Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D. Zelenetz, Franck Morschhauser, Gilles Salles et al.|Blood|2019Cited by 136
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, Stephan Mielke et al.|Nature Medicine|2024Cited by 127
The Lymphoid Variant of Hypereosinophilic SyndromeGuillaume Lefèvre, Jean‐Emmanuel Kahn, Marie‐Christine Copin et al.|Medicine|2014Cited by 122
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysisMassimo Federico, Bertrand Coiffier, María Dolores Caballero Barrigón et al.|The Lancet Haematology|2018Cited by 116
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37